Center for Cancer Immunology and Immunotherapy (CCII)

癌症免疫学和免疫治疗中心 (CCII)

• 批准号: 10753949
• 负责人: Jason A. Chesney
• 金额: $ 26.07万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10753949
• 关键词: Adoptive Cell Transfers; Advanced Malignant Neoplasm; Advisory Committees; Animals; Antibodies; Area; Award; Basic Science; Bioinformatics; Biological Markers; Biomedical Research; Biometry; Bladder; CAR T cell therapy; CTLA4 gene; Cancer Center; Cancer Death Rates; Centers of Research Excellence; Clinical; Clinical Trials; Collaborations; Conduct Clinical Trials; Country; Cytometry; Development; Diagnosis; Discipline; Disease remission; Disseminated Malignant Neoplasm; Early Diagnosis; Financial Support; Flow Cytometry; Funding; Future; Genomics; Goals; Grant; Growth; Head and neck structure; Home; Human; Immune; Immune Evasion; Immune checkpoint inhibitor; Immune response; Immune system; Immunologic Surveillance; Immunologist; Immunotherapeutic agent; Immunotherapy; Infrastructure; Institution; Interdisciplinary Study; International; Investments; Kidney; Lung; Malignant Neoplasms; Mediating; Mentors; Mission; Molecular; Mus; Names; Oncolytic viruses; Outcome; Paper; Patients; Personnel Selection; Persons; Phase; Pilot Projects; Proteins; Publications; Qualifying; Recording of previous events; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Resistance; Resources; Sampling; Seminal; Services; Specimen; Study Section; T cell therapy; Talents; Testing; Training; Translating; Translational Research; Tumor Immunity; Universities; Vaccines; Work; anti-cancer; cancer cell; cancer clinical trial; cancer immunotherapy; cancer therapy; cancer type; career development; checkpoint therapy; chimeric antigen receptor T cells; cohort; equipment acquisition; immune checkpoint; improved; innovation; interest; melanoma; member; microbiome research; new therapeutic target; novel strategies; novel therapeutic intervention; optimism; programmed cell death ligand 1; programmed cell death protein 1; programs; recruit; research and development; response; senior faculty; side effect; statistics; success; systemic toxicity; treatment strategy; tumor; tumor immunology

The objective of this program is to establish a thematic multidisciplinary research center of excellence at the University of Louisville (UofL) named the Center for Cancer Immunology and Immunotherapy (CCII). The mission of the CCII is to conduct outstanding biomedical research that works towards harnessing the power of the immune system to eradicate cancer. There is currently a great deal of optimism about the prospects for cancer immunotherapies given the recent clinical successes of immune checkpoint inhibitors, oncolytic viruses, and adoptive cell transfer therapies. Immunotherapies have the potential to be used to treat all types of cancer and to induce long-lasting remissions or cures. However, more research and development is needed for cancer immunotherapy to reach its full potential. The University of Louisville is exceptionally qualified to be the home of the CCII for many reasons including our 10-year track record of conducting clinical trials of immunotherapeutic agents, unique resources that include access to human specimens from these trials, our senior investigators’ expertise in cancer immunology, our focus on translational research, and the impact that this COBRE would have in a state with the highest cancer death rates in the nation. Importantly, the University of Louisville is highly invested in making this proposed center a success as best evidenced by more than $16.8M in institutional commitments over five years. The two PIs of the CCII program are highly regarded experts in the field who have made seminal contributions spanning from basic cancer immunology to pivotal clinical trials of cancer immunotherapies. Senior mentors with expertise in the thematic area and a strong history of funding, publications, mentoring, and study section service will support the CCII’s mentoring mission, as will a team of co-investigators with essential expertise (in administration, biostatistics, and bioinformatics) and Internal and External Advisory Committees. A Functional Immunomics Core will provide important new infrastructure and leverage existing resources (including other IDeA programs) to provide outstanding support to the four promising junior investigators who have been selected as the first cohort of CCII Project PIs. The four overall specific aims of the CCII are to: (1) Establish the administrative and mentoring infrastructure for the CCII; (2) Create a research core that provides new capabilities while leveraging existing facilities; (3) Support the research and career development of junior PIs in the thematic area; and (4) Develop and initiate a plan for long-term sustainability and growth of the CCII. We are confident that this new COBRE center will lead to the awarding of innovative R01 grants for 4-6 CCII junior investigators in the first five years and that many of these graduates will remain key members of this new COBRE to further build the center in the future. Most importantly, our combination of rigorous basic science with highly translational animal and human specimen studies should ultimately contribute to the development of new treatment strategies that will help to improve the outlook for the more than 17 million people worldwide who are diagnosed with cancer each year.

该计划的目的是在建立一个主题跨学科研究中心 路易斯维尔大学（UOFL）被任命为癌症免疫学和免疫疗法中心（CCII）。这 CCII的使命是进行杰出的生物医学研究，以利用 放射性癌的免疫系统。目前对前景有很多乐观 鉴于免疫抑制剂，溶瘤病毒，癌症免疫疗法，癌症 和自适应细胞转移疗法。免疫疗法有可能用于治疗所有类型的癌症 并诱发持久的恢复或治疗方法。但是，需要更多的研发 癌症免疫疗法具有全部潜力。路易斯维尔大学非常有资格成为 CCII的故乡出于许多原因，包括我们进行10年的临床试验记录 免疫治疗剂，独特的资源，包括从这些试验中访问人类标本的独特资源，我们 高级研究者在癌症免疫学方面的专业知识，我们对转化研究的关注以及 这种毛绒将处于全国癌症死亡率最高的州。重要的是，大学 路易斯维尔（Louisville）的投入高度投入在使这一拟议中心取得成功，而最能证明 五年来的机构承诺为1680万美元。 CCII计划的两个PI被高度评价 该领域的专家已做出了从基本癌症免疫学到关键的第二次贡献 癌症免疫疗法的临床试验。具有专业知识的高级导师在主题领域和强大 资金，出版物，心理和学习部门的历史将支持CCII的心理任务， 与具有基本专业知识（行政，生物统计学和生物信息学）的共同投资者团队一样 以及内部和外部咨询委员会。功能性免疫学核心将提供重要的新 基础架构并利用现有资源（包括其他想法计划）提供出色的支持 被选为CCII Project PIS的第一个队列的四名有前途的初级调查员。这 CCII的四个总体特定目标是：（1）建立为该行政和心理基础设施 ccii; （2）创建一个研究核心，可在利用现有设施的同时提供新的功能； （3）支持 主题领域初级PI的研究和职业发展； （4）制定并启动计划 CCII的长期可持续性和增长。我们有信心这个新的毛绒中心将导致 在头五年中，授予4-6个CCII初级调查人员的创新R01赠款，其中许多 毕业生将仍然是该新山羊的主要成员，以便将来进一步建立该中心。最多 重要的是，我们严格的基础科学与高度翻译的动物和人类标本的结合 研究最终应为制定新的治疗策略做出贡献，以帮助改善 全球超过1700万人每年被诊断出患有癌症的人的前景。